- Home
- MGF vs KZIA Comparison
MGF vs KZIA Comparison
Compare MGF & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGF | KZIA |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 93.2M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | MGF | KZIA |
|---|---|---|
| Price | $2.93 | $7.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 104.3K | ★ 163.6K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 7.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $0.64 |
| 52 Week High | $3.17 | $17.40 |
Technical Indicators
Market Signals| Indicator | MGF | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 51.07 |
| Support Level | $2.92 | $7.54 |
| Resistance Level | $3.12 | $7.86 |
| Average True Range (ATR) | 0.03 | 0.99 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 33.33 | 21.37 |
Price Performance
Historical ComparisonAbout MGF MFS Government Markets Income Trust
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.